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Aims We studied the inﬂuence of heart rate (HR), systolic blood pressure (SBP), and beta-blocker dose
on outcome in the 2599 out of 3029 patients in Carvedilol Or Metoprolol European Trial (COMET) who
were alive and on study drug at 4 months after randomization (time of ﬁrst visit on maintenance
therapy).
Methods and results By multivariable analysis, baseline HR, baseline SBP, and their change after 4
months were not independently related to subsequent outcome. In a multivariable analysis including
clinical variables, HR above and SBP below the median value achieved at 4 months predicted subsequent
increased mortality [relative risk (RR) for HR. 68 b.p.m. 1.333; 95% conﬁdence intervals (CI)
1.152–1.542; P, 0.0001 and RR for SBP. 120 mmHg 0.78; 95% CI 0.671–0.907; P, 0.0013]. Achieving
target beta-blocker dose was associated with a better outcome (RR 0.779; 95% CI 0.662–0.916;
P, 0.0025). The superiority of carvedilol as compared to metoprolol tartrate was maintained in a mul-
tivariable model (RR 0.767; 95% CI 0.663–0.887; P ¼ 0.0004) and there was no interaction with HR, SBP,
or beta-blocker dose.
Conclusion Beta-blocker dose, HR, and SBP achieved during beta-blocker therapy have independent
prognostic value in heart failure. None of these factors inﬂuenced the beneﬁcial effects of carvedilol
when compared with metoprolol tartrate at the pre-deﬁned target doses used in COMET.
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Introduction
Treatment with beta-blockers has been shown to improve
survival in patients with chronic heart failure (CHF) and
the beneﬁt of the three agents, carvedilol,1,2 metoprolol,3
and bisoprolol,4 has been documented. These agents have
important pharmacological differences. Each blocks beta1-
adrenergic receptors, but only carvedilol blocks beta2- and
alpha1-adrenergic receptors and has further antiprolifera-
tive, antioxidant, and anti-endothelin actions.5,6 Previous
studies have shown that carvedilol improves left ventricular
(LV) function more than metoprolol,7–9 and in the Carvedilol
Or Metoprolol European Trial (COMET),10 carvedilol signiﬁ-
cantly reduced all-cause mortality when compared with
metoprolol tartrate. In this trial, carvedilol was associated
with a slight, but signiﬁcantly greater decrease in both
heart rate (HR) and systolic blood pressure (SBP) after 4
months of treatment when compared with metoprolol tar-
trate. Furthermore, not all patients reached the target
beta-blocker dose in either study group.10 As all of these
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factors may inﬂuence mortality in CHF patients,5,11,12 we
have analysed their relationships to the outcome, as well
as to the differences observed between carvedilol and meto-
prolol tartrate.
Methods
The COMET design has been published previously.10,13 In summary,
COMET was a multicentre, randomized, double-blind, parallel-
group trial comparing the effect on mortality and morbidity of
carvedilol and metoprolol tartrate in patients with symptomatic
chronic CHF [New York Heart Association (NYHA) class II–IV] associ-
ated with LV systolic dysfunction (ejection fraction 0.35), at least
one cardiovascular hospitalization during the 2 years before trial
entry, optimal baseline therapy, including the need for diuretic
therapy. Among the exclusion criteria were baseline resting HR
,60 b.p.m. and SBP ,85 mmHg. COMET was designed as an
event-driven study with co-primary endpoints of all-cause mortality
and the combined endpoint of mortality or hospitalization for any
cause. Patients were randomized to carvedilol or metoprolol tar-
trate and received initial doses of 3.125 mg or 5 mg twice daily
(b.i.d.), respectively. Doses were doubled at 2 week intervals,
aiming for target doses of 25 mg b.i.d. of carvedilol and 50 mg
b.i.d. of metoprolol tartrate. During up-titration, dosing could
be adjusted and, if necessary, delayed by the investigator on the
basis of symptoms or intolerance. Therefore, the titration phase
could take up to 14 weeks from randomization. When patients
reached the target or the maximally tolerated dose, the mainten-
ance phase began. All patients underwent clinical assessment,
Table 1 Baseline characteristics of COMET patients by status at 4 months
Alive on trial
medication
(n ¼ 2599)
Dead
(n ¼ 111)
Alive, stopped
trial medication
(n ¼ 319)
P-value
Age (years) 61.6+ 11.3 63.9+ 12.4 64.6+ 11.4 ,0.0001
Gender (% male) 79.7 82.0 79.9 0.8382
Body mass index (Kg/m2) 26.9+ 4.4 26.1+ 4.7 26.3+ 4.5 0.0119
SBP (mmHg) 126.8+ 19.2 114.5+ 17.1 123.9+ 20.9 ,0.0001
DBP (mmHg) 77.5+ 10.7 72.2+ 10.6 75.8+ 11.9 ,0.0001
HR (b.p.m) 81.2+ 13.4 82.0+ 13.6 79.7+ 13.1 0.1192
NYHA class (%)
II 51.4 24.3 32.0 ,0.0001
III 45.7 63.1 59.9
IV 2.9 12.6 8.2
CHF duration (months) mean/median 40.5/19.0 60.5/35.0 51.7/30.0 ,0.0001
Aetiology (%)
Ischaemic Heart Disease 50.9 60.4 63.0 0.0001
Hypertension 17.7 15.3 18.5 0.7513
Dilated cardiomyopathy 45.7 34.2 32.6 ,0.0001
Previous valve surgery 2.4 1.8 3.1 0.6665
LV EF (%) 26.1+ 7.1 24.1+ 7.4 26.4+ 7.6 0.0148
NT-proBNP (pg/mL) median 1149 2350 1600 0.0001
Associated diagnosis (%)
Previous MI 39.9 52.8 51.3 ,0.0001
CAD (by angiography) 56.7 73.5 71.9 ,0.0001
Current angina 20.7 30.3 26.5 0.0049
Hypertension 37.1 30.3 37.6 0.3389
Diabetes 23.5 24.5 29.5 0.0635
Stroke 7.1 5.5 7.5 0.7631
ECG ﬁndings (%)
Sinus rhythm 76.0 60.4 68.0 ,0.0001
Atrial ﬁbrillation/ﬂutter 19.2 26.1 22.6 0.0851
Paced rhythm 5.7 11.7 11.6 ,0.0001
Concomitant medication at
randomization (%)
Diuretics 98.7 100.0 98.1 0.3107
ACE inhibitors 91.7 86.5 90.3 0.1248
Angiotensin receptor antagonists 6.4 7.2 7.5 0.7099
Digitalis 59.3 66.7 57.7 0.2433
Antiarrhythmics 11.0 20.7 18.2 ,0.0001
Nitrates 31.5 44.1 39.2 0.0007
Aldosterone antagonists 10.6 16.2 10.7 0.1723
Beta-blockers (before study started) 4.7 1.8 1.6 0.0131
Anticoagulants 45.7 51.4 44.2 0.4237
Aspirin 36.2 36.0 42.3 0.1005
Lipid lowering agents (statins) 21.3 16.2 21.0 0.4349
P-value refers to signiﬁcance of differences between the patients alive on trial medication vs. the patients who died or those who stopped the trial
medication, considered together.
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; %, percent of patients.
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including HR and blood pressure measurements at 4 months after
randomization when they were receiving a stable beta-blocker
regimen. As this was the ﬁrst visit during the maintenance phase
after completion of beta-blocker up-titration, this visit was used
to classify patients according to their HR and SBP response and
study medication dose.
Statistical analysis
Results are expressed as mean+ SD unless otherwise speciﬁed.
Differences were assessed by t-tests for continuous variables and by
the x2 test for categorical data. Kaplan–Meier survival estimates
were also calculated. To assess the impact on mortality of SBP, HR,
and dose at baseline and at 4 months, we ﬁtted multivariable Cox
regression models. These models included 10 baseline factors
shown to be important for prognostic assessment in previous
studies:11,12,14 age, gender, NYHA classiﬁcation, ischaemic aetiology,
left ventricular ejection fraction, diabetes, digitalis, haemoglobin,
serum sodium and creatinine, and randomized therapy. For dose,
comparisons were made between those patients who were on
target doses (carvedilol 25 mg b.i.d. or metoprolol tartrate 50 mg
b.i.d.) and those on lower doses 4 months after randomization. To
assess the best functional form to use for the HR and SBP variables,
we calculated Martingale residuals from ﬁtted Cox regression
models. These residuals suggested that cutting these variables
below and above the median not only made interpretation easier,
but also matched the functional form of the predictors very well.
Hence, throughout this manuscript the majority of results are
presented using these splits. We also performed sensitivity analyses,
reported in the text, both splitting the data into quartiles and treat-
ing these variables as continuous factors. To assess the proportional
hazards assumption, we plotted the rescaled Scoenfeld residuals
over time for each parameter and examined the resulting plots.15
Results are based on available data with no attempt to replace
missing values. All hypothesis tests reported are two-sided and use
a P-value ,0.05 as signiﬁcant. Although multiple analyses are pre-
sented, the purpose is to better understand the differences observed
in mortality between carvedilol and metoprolol for which the type I
error was well controlled. These analyses are therefore exploratory
and no adjustment for the multiple assessments is necessary.
Results
Patient population
In COMET, 3029 patients were randomized to carvedilol
(1511 patients) or to metoprolol tartrate (1518 patients).
Median study duration was 58 months (interquartile range
54–64). Five patients were lost to follow-up and 28 patients
withdrew their consent during the trial. All other patients
were followed until death or study end.10 During the ﬁrst
4 months of beta-blocker therapy, 111 patients died (53 on
carvedilol and 58 on metoprolol tartrate) and 319 patients
(161 on carvedilol and 158 on metoprolol tartrate) were
withdrawn from study medication. The present analyses,
except for baseline, include the remaining 2599 patients
alive and on study medication at 4 months. Their character-
istics are compared with those of the patients who died or
were discontinued during the ﬁrst 4 months (Table 1 ).
Baseline HR and SBP
The number of patients in the carvedilol and metoprolol
tartrate groups for HR and SBP are shown in Figure 1. The
Figure 1 Time course of HR and BP in patients randomized to carvedilol and metoprolol tartrate. Upper graphs show all patients who were on treatment at the
time of measurement. Lower graphs show per cent of patients on carvedilol and metoprolol tartrate in subgroups according to median HR and SBP at baseline,
after 4 months, and by change from baseline at 4 months. P , 0.05, P , 0.01 and P, 0.001 for comparison between the patients on carvedilol versus those
on metoprolol tartrate.
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Table 2 Baseline patient characteristics by HR, SBP, and study drug dose subgroups
Baseline HR HR at 4 months Baseline SBP SBP at 4 months Beta-blocker dose
80 b.p.m.
(n ¼ 1443)
.80 b.p.m.
(n ¼ 1136)
68 b.p.m.
(n ¼ 1422)
.68 b.p.m.
(n ¼ 1160)
120 mmHg
(n ¼ 1236)
.120 mmHg
(n ¼ 1353)
120 mmHg
(n ¼ 1357)
.120 mmHg
(n ¼ 1234)
Below target
(n ¼ 615)
Target
(n ¼ 1980)
Age (years) 62.4+ 10.9 60.5+ 11.7 63.1+ 10.7 59.7+ 11.7 60.1+ 11.5 62.9+ 10.9 60.7+ 11.5 62.5+ 10.9 63.6+ 11.2 61.0+ 11.2
Gender (% male) 82.7 76.1 81.2 77.9 81.9 77.8 80.0 79.5 77.8 80.4
Body mass index (Kg/m2) 26.7+ 4.0 27.3+ 4.8 26.8+ 4.3 27.2+ 4.5 26.2+ 4.2 27.6+ 4.5 26.4+ 4.3 27.6+ 4.4 26.1+ 4.1 27.2+ 4.4
SBP (mmHg) 126+ 18 127+ 20 127+ 19 127+ 19 111+ 9 142+ 13 118+ 16 136+ 18 122+ 19 128+ 19
Diastolic blood pressure
(mmHg)
77+ 11 79+ 11 77+ 10 78+ 11 72+ 8 83+ 10 74+ 10 81+ 11 75+ 11 78+ 11
HR (b.p.m.) 71.7+ 6.3 93.4+ 9.7 77.0+ 11.7 86.4+ 13.5 81.4+ 13.5 81.1+ 13.2 81.6+ 13.6 80.8+ 13.1 79+ 13 82+ 13
NYHA class (%)
II 54.1 48.3 52.5 50.5 48.6 54.1 48.7 54.6 39.4 54.9
III 43.6 48.2 44.4 46.9 47.7 43.8 47.8 43.2 54.8 43.1
IV 2.4 3.5 3.1 2.6 3.6 2.1 3.5 2.2 5.8 2.0
CHF duration (months)
mean/median
41.7/20.0 39.1/19.0 39.5/19.0 41.7/20.0 42.0/21.0 39.1/18.0 43.0/22.0 37.7/17.0 45.7/26.0 39.0/17.0
Aetiology (%)
Ischaemic heart disease 53.9 47.0 55.1 45.7 51.5 50.4 54.0 47.4 61.4 48.0
Hypertension 17.6 18.0 17.9 17.5 9.9 25.1 10.6 25.7 19.0 17.4
Dilated cardiomyopathy 42.7 49.9 41.1 51.7 47.8 44.0 45.3 46.4 35.4 48.6
Previous valve surgery 2.4 2.2 2.0 2.8 2.8 1.8 2.2 2.4 3.2 2.2
LV EF (%) 26.7+ 6.9 25.3+ 7.2 26.4+ 7.1 25.7+ 7.0 25.0+ 7.2 27.1+ 6.8 25.2+ 7.2 27.1+ 6.8 26.0+ 7.0 26.2+ 7.1
NT-proBNP (pg/mL) median 1128 1232 1137 1196 1388 1033 1301 1057 1570 1089
Associated diagnosis (%)
Previous MI 44.3 34.2 45.0 33.7 41.9 38.1 44.8 34.4 49.2 37.3
CAD (by angiography) 58.0 54.7 60.3 52.1 56.1 57.2 59.2 53.5 65.4 54.1
Current angina 22.7 18.1 23.5 17.3 20.0 21.3 21.3 20.0 23.7 20.0
Hypertension 35.6 38.8 36.3 37.9 25.1 47.9 26.4 48.7 37.5 36.8
Diabetes 21.7 25.8 21.2 26.3 20.0 26.7 19.6 27.7 23.7 23.6
Stroke 7.3 6.6 7.7 6.2 6.1 8.1 7.1 7.1 8.9 6.8
ECG ﬁndings (%)
Sinus rhythm 75.8 76.2 79.0 72.2 76.4 75.8 74.7 77.6 73.6 76.3
Atrial ﬁbrillation/ﬂutter 17.8 21.0 17.1 21.8 17.5 20.7 19.2 19.1 19.5 19.3
Paced rhythm 7.4 3.4 4.1 7.7 6.9 4.6 6.9 4.3 7.9 5.2
Continued
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baseline characteristics and the differences among the
patients in these groups are shown in Table 2.
Baseline HR had no relationship to mortality. These results
were similar both when we analysed all the 3029 patients
randomized in COMET and when our analysis was restricted
to only the 2599 patients on study medication at 4 months.
In contrast, baseline SBP had a signiﬁcant relationship to
outcome both when all the patients and those on study
medication at 4 months were analysed (Figure 2 ). However,
the predictive value of baseline SBP was superseded by that
of SBP measured at 4 months.
Change in HR and SBP after 4 months
Mean HR decreased from baseline by 13.3+ 13.4 b.p.m. in
the carvedilol group and by 11.7+ 13.5 b.p.m. in the meto-
prolol tartrate group at 4months (21.6+ 13.4 b.p.m., 95%CI
22.7 to 20.6 b.p.m.; P ¼ 0.0022 for carvedilol vs.
metoprolol tartrate). HR was slightly but signiﬁcantly lower
in the carvedilol group when compared with the metoprolol
tartrate group also at 8 and 16 months after randomization
(21.7+ 14.3 b.p.m.; P ¼ 0.0034 and 21.8+ 14.3 b.p.m.;
P ¼ 0.0040, respectively). No signiﬁcant differences were
observed at further visits during the 5 years after randomiz-
ation. SBP decreased from baseline by 3.8+ 17.4 mmHg in
the carvedilol group and by 2.0+17.7 mmHg in the metopro-
lol tartrate group (P ¼ 0.0094) at 4 months. The difference
remained signiﬁcant during most of the follow-up (Figure 1 ).
There was no relationship between changes in HR or SBP
during the ﬁrst 4 months of treatment and mortality. A HR
68 b.p.m. and a SBP .120 mmHg (median values) at 4
months were associated with a better outcome (Figure 2 ).
Exclusion of patients with atrial ﬁbrillation and/or those
with a permanent pacemaker did not change these results
(data not shown).
Beta-blocker dose
The mean daily dose of study drug at entry into the mainten-
ance phase was 41.9+ 14.7 mg in the carvedilol group and
84.9+ 29.2 mg in the metoprolol tartrate group. The
target doses of 25 mg b.i.d. of carvedilol and of 50 mg
b.i.d. of metoprolol tartrate were reached in 75 and 78%
of the patients, respectively. Achievement of the target
beta-blocker doses was associated with a lower mortality
(Figure 2 ).
Multivariable analysis
To assess the impact on mortality of SBP, HR, beta-blocker
dose and randomized therapy, these variables were
entered in a multivariable model including other baseline
factors shown to be important in previous studies.11,12,14
Variables signiﬁcantly related to subsequent mortality are
shown in Table 3. Among the haemodynamic variables, the
only ones which had independent prognostic value were
the HR and the SBP assessed at 4 months. The beta-
blocker dose level administered at 4 months had indepen-
dent prognostic value as well (Figure 3 ).
Treatment effect
Mortality was lower in the carvedilol group than in the
metoprolol tartrate group in each deﬁned group of HR,
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SBP, and study drug dose (Figures 3 and 4 ), and the beneﬁt
of carvedilol was similar in each group. Similar models using
quartiles and treating the HR and SBP as continuous predic-
tors are shown in Table 4. The conclusions were not
different.
In the multivariable analysis, the superiority of carvedilol
compared with metoprolol tartrate was maintained
[relative risk (RR) 0.767; 95% CI 0.663–0.887; P ¼ 0.0004],
and there was no interaction between study drug and any
other variable in the ﬁnal model (all P-values for
interaction . 0.10).
Discussion
We have examined the relationships between HR, SBP,
achieved beta-blocker dose, and outcomes in COMET and
found that the HR and SBP values after 4 months from
initiation of beta-blocker therapy and beta-blocker dose
have independent prognostic value for subsequent mortality
in CHF patients. However, these variables could not explain
the differences observed between carvedilol and metoprolol
tartrate on reducing mortality in the COMET study.
Heart rate
By multivariable analysis, neither baseline HR nor its change
after 4 months of therapy was related to prognosis. These
data contrast with some previous studies showing that HR
is an independent prognostic factor in CHF.11,12 Previous
studies had also shown that enalapril,16 amiodarone,17 and
beta-blockers18,19 may exert greater beneﬁt in the patients
with faster HR. In the CIBIS-I trial, the achieved HR after 2
months of therapy was an important prognostic factor.20 In
the CIBIS-II trial, baseline HR and HR change at 2 months
predicted outcome. However, this appeared to be related
to the adverse prognosis of patients in whom HR had
increased, a possible marker of non-compliance with the
beta-blocker.21 Other studies could not establish any
relationship between the baseline HR and the efﬁcacy of
beta-blocker therapy with either non-selective agents22,23
or selective agents24,25. In the MERIT-HF trial, metoprolol
CR/XL signiﬁcantly reduced mortality and hospitalizations
independent of resting baseline HR, achieved HR, and
Figure 2 RR of death in subgroups based on median HR and SBP values and by study drug target dose achieved, adjusted for the other baseline variables.
Table 3 Predictors of death by multivariable analysis
RR 95% CI P-value
Carvedilol vs. metoprolol 0.767 0.663, 0.887 0.0004
HR at 4 months,
.68 b.p.m.
1.333 1.152, 1.542 0.0001
SBP at 4 months
.120 mmHg
0.78 0.671, 0.907 0.0013
High dose vs. low dose 0.779 0.662, 0.916 0.0025
Increasing age (years) 1.038 1.03, 1.046 ,0.0001
Female vs. male 0.667 0.547, 0.813 0.0001
NYHA class III vs. NYHA
class II
1.293 1.11, 1.508 0.001
NYHA class IV vs. NYHA
class II
1.703 1.191, 2.437 0.0036
Ischaemic aetiology 1.333 1.138, 1.561 0.0004
Increasing LVEF (%) 0.975 0.965, 0.985 ,0.0001
Diabetes 1.328 1.129, 1.562 0.0006
Digitalis 1.523 1.305, 1.778 ,0.0001
Increasing haemoglobin
(g/dL)
0.896 0.852, 0.941 ,0.0001
Increasing sodium
(mmol/L)
0.956 0.935, 0.977 ,0.0001
Increasing creatinine
(mmol/L)
1.002 1.001, 1.003 0.0002
LVEF, left ventricular ejection fraction.
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change in HR.25 The reduction in mortality with bisoprolol,
when compared with placebo, was not inﬂuenced by HR
changes in CIBIS-II as well.21 It is likely that beta-blocker
therapy may counteract the deleterious effects of tachycar-
dia in the failing heart so that this variable loses its prognos-
tic signiﬁcance.
Another difference between CIBIS-II and COMET is the role
of cardiac rhythm. In CIBIS-II, the coexistence of atrial
ﬁbrillation was associated with a lack of difference in mor-
tality between bisoprolol and placebo.21 In contrast, base-
line atrial ﬁbrillation did not inﬂuence the results of
COMET and of other trials.26 The CIBIS-II ﬁndings on atrial
ﬁbrillation were therefore possibly due to chance.
In contrast to baseline data, the HR assessed at 4 months
after the initiation of beta-blocker therapy had an indepen-
dent prognostic value for subsequent outcome. Although
Figure 3 Kaplan–Meier curves of the deﬁned patient subgroups based on 4 months HR, SBP, and achieved beta-blocker dose. Meto indicates metoprolol tartrate
and Carv indicates carvedilol.
Figure 4 RR of death in subgroups based on median HR and SBP values and by study drug dose achieved, according to treatment group (carvedilol or metoprolol
tartrate).
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peak exercise HR provides a more accurate assessment of
the degree of beta1-blockade,
27 resting HR is the variable
most frequently used to assess the level of beta-blockade
in clinical practice. Our ﬁndings emphasize the importance
of achieving adequate beta-blockade and/or HR lowering
in CHF patients.
Our study shows that the difference in mortality, observed
between carvedilol and metoprolol tartrate in COMET, was
independent of baseline HR, its values after 4 months of
treatment, and its changes. These results are important
for the interpretation of the mortality results of COMET.10
Some authors have suggested that these results may just
reﬂect the different levels of beta1-receptor blockade
achieved with the doses of carvedilol and metoprolol tar-
trate administered in this trial. The difference in the 4
month resting HR between the two treatments has been
used as evidence of this.28,29 It is known that resting HR is
only weakly related to beta1-receptor stimulation as it is
inﬂuenced by many other factors, such as beta2-receptors
stimulation, vagal activity, and epinephrine levels, so that
the level of beta1-receptor blockade is better predicted by
peak exercise HR or mean 24 h HR.9,27,30 However, neither
of these variables was assessed in COMET. Hence, our analy-
sis is not optimal for assessing whether similar levels of
beta1-receptor blockade were achieved with carvedilol
and metoprolol tartrate in COMET. However, as far as the
level of beta1-receptor blocking is reﬂected in the resting
HR, we have shown that having adjusted for this, the signiﬁ-
cance and, more importantly, the magnitude of the mortality
beneﬁt of carvedilol vs. metoprolol tartrate remained
unchanged. We can therefore state that the small difference
in the 4 month resting HR was not responsible for the mor-
tality difference seen in COMET. These results are consistent
with the speciﬁc pharmacological characteristics of carvedi-
lol, such as its tighter binding to the beta1-receptors,
31,32
beta2-receptor blockade,
27,33 or increased beta2-receptor
coupling with the Gi proteins.34
Systolic blood pressure
Baseline SBP was related to prognosis by univariate analysis.
The patients with a baseline SBP 120 mmHg had a 24%
higher risk of death when compared with those with a SBP
.120 mmHg (P ¼ 0.0001). This is in agreement with pre-
vious studies.11,12,21 It is likely that patients with lower
SBP have poorer LV systolic function and hence a poorer
outcome. A correlation between SBP and a greater beneﬁt
from beta-blocker therapy has been found in previous
studies.21,22,24 A recent analysis of the COPERNICUS study,
which, unlike other beta-blocker trials, included patients
with a SBP as low as 85 mmHg, showed that the absolute
beneﬁt from carvedilol, when compared with placebo, is
maintained and even greater in patients with the lowest
SBP (85–95 mmHg) because of their highest risk.35 When
assessed in a multivariable model including the variables
measured 4 months after the initiation of beta-blocker
therapy, the SBP at 4 months replaced the baseline measure-
ments which lost their predictive value. This may reﬂect the
profound effects of beta-blockers on both the haemo-
dynamic variables and their prognostic value, so that they
have a greater signiﬁcance when measured during therapy.
The correlation between a higher SBP value, during beta-
blocker treatment, and a better outcome contradicts the
hypothesis that the beneﬁcial effects of carvedilol were
related to its greater hypotensive action in COMET.
Moreover, similar to HR, the effects of carvedilol on
mortality were not inﬂuenced by SBP.
Beta-blocker dose
Treatment with less than target doses of either carvedilol or
metoprolol tartrate was a strong and independent predictor
of a poor prognosis in COMET. The patients receiving
reduced doses at 4 months had signs of more advanced
CHF. They were also older, more likely to have ischaemic
Table 4 Predictors of death by multivariable analysis—alternative models
RR 95% CI P-value
Splitting HR and SBP into
quartiles
Carvedilol vs. Metoprolol 0.767 0.663, 0.888 0.0004
HR at 4 months, ,60 b.p.m. Reference
HR at 4 months, 60–68 b.p.m. 1.019 0.834, 1.245 0.8529
HR at 4 months, 68–76 b.p.m. 1.349 1.102, 1.651 0.0038
HR at 4 months, .76 b.p.m. 1.339 1.089, 1.645 0.0055
SBP at 4 months, ,110 mmHg Reference
SBP at 4 months, 110–120 mmHg 0.92 0.754, 1.121 0.4069
SBP at 4 months, 120–140 mmHg 0.723 0.601, 0.871 0.0006
SBP at 4 months, .140 mmHg 0.826 0.656, 1.04 0.1045
High dose vs. low dose 0.777 0.66, 0.915 0.0025
Treating HR and SBP as
continuous predictors
Carvedilol vs. metoprolol 0.765 0.661, 0.885 0.0003
Increasing 4 months HR (b.p.m.) 1.008 1.002, 1.013 0.0114
Increasing 4 months SBP (mmHg) 0.994 0.99, 0.998 0.0038
High dose vs. low dose 0.781 0.663, 0.919 0.0029
RRs are calculated using as reference the lowest quartile (e.g. HR ,60 b.p.m. and SBP ,110 mmHg).
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heart disease and not to tolerate an ACE-inhibitor. The prog-
nostic value of the beta-blocker dose remained signiﬁcant
after adjustment for the other baseline variables. These
data conﬁrm previous studies showing that intolerance of
target beta-blocker doses is associated with more severe
symptoms and a worse prognosis.36,37 Intolerance to beta-
blocker therapy had similar consequences for metoprolol
tartrate and carvedilol and these results shed no light on
the question of whether the differences in mortality
between carvedilol and metoprolol have any bearing on
dose. Multivariable analysis found no interaction between
high and low achieved doses of metoprolol tartrate and
carvedilol and the beneﬁcial effects of carvedilol, when
compared with metoprolol tartrate, on outcome.
Limitations of the study
This is a post hoc analysis focusing on events which occurred
later than 4 months after randomization. Focusing on post-
randomization changes creates a risk of bias as it excludes
the patients who died or who discontinued the study medi-
cation during the ﬁrst 4 months. We therefore had to
exclude 430/3029 patients (15%). However, the inclusion
of the haemodynamic measurements at 4 months is import-
ant as, at this time interval, most patients were titrated to
their ﬁnal beta-blocker doses and, thus, the role of the
changes in HR or SBP caused by the two beta-blockers
could be assessed. Accordingly, the 4 months changes in
HR and SBP were the focus of the controversy regarding
the magnitude of the beta1-receptors blockade achieved
with the two beta-blockers.28,29
Conclusions
Our results show that the survival of patients with CHF on
long-term beta-blocker treatment is related neither to
their HR nor to their SBP before the initiation of beta-
blocker therapy or to their subsequent changes. In contrast,
the HR and SBP achieved on maintenance beta-blocker
therapy and beta-blocker dose have independent prognostic
value. The beneﬁcial effects of carvedilol, when compared
with metoprolol tartrate, at the pre-deﬁned target doses
of each compound, on mortality could not be explained by
the differences in BP and HR observed after 4 months of
study treatment or by patients not achieving target study
drug levels.
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